Rebio-Science-B (06938) conducted its IPO from December 31st to January 6th, receiving approximately 100 million US dollars in cornerstone investment subscriptions.

Ruibo Biotech-B (06938) will launch its IPO from December 31, 2025 to January 6, 2026, intending to globally sell 27.4874 million H shares. Of these, 10% will be sold in Hong Kong and 90% internationally, with an additional 15% of over-allotment option. The offering price will be HK$57.97 per share, with trading units of 200 H shares per lot. It is expected that H shares will start trading on the Hong Kong Stock Exchange on January 9, 2026 (Friday) at 9 am. We are a biopharmaceutical company specializing in the research and development of small nucleic acid drugs, particularly focusing on siRNA therapy. Our core product is RBD4059 (siRNA targeting FXI) for the treatment of thrombotic diseases. We have a total of seven self-developed drug assets in clinical trials, covering seven indications including cardiovascular, metabolic, kidney, and liver diseases, with four in Phase 2 clinical trials. In addition to our core product RBD4059, we are also advancing other clinical stage products, including RBD5044 and RBD1016. RBD5044 is the world's second siRNA drug targeting APOC3 (a protein involved in lipid metabolism) to enter clinical development. RBD1016 targets HBsAg, aiming for functional cure of CHB, and is also a differentiated siRNA candidate drug for CHD. Outside of the clinical pipeline, we have over 20 preclinical projects planned to advance to the clinical development stage. We have entered into cornerstone investment agreements with Arc Avenue, Bright Stone, Huaxia Fund, Da Cheng International and Da Cheng Fund, Erik Selin Fastigheter AB, Himension Fund, IvyRock, Mingxin Growth Ventures, Springs Capital (Hong Kong), Taikang Life and Shibei Nengxin, Nature Shibei and Huatai Capital Investment Limited (regarding Huatai OTC derivatives), where cornerstone investors have agreed to subscribe or cause their designated entities to subscribe to the sale shares in an aggregate amount of approximately USD 100 million at the offer price, subject to certain conditions being met. We believe that the cornerstone allocation reflects the confidence of our cornerstone investors in our company and its business prospects, and the cornerstone allocation will help enhance our company's image. In addition to the main shareholder of Ribocure AB, Erik Selin Fastigheter Aktiebolag (Erik Selin Fastigheter AB), we have introduced various cornerstone investors through the overall coordinator of the global offering. Based on the offer price of HK$57.97 per share and assuming the exercise of the over-allotment option and additional allotment rights, we estimate that we will receive net proceeds of approximately HK$1.474 billion from the global offering. Approximately 37.4% will be used for the research and development of the core product RBD4059; approximately 19.6% will be used for the research and development of RBD5044; approximately 15.9% will be used for the research and development of RBD1016; approximately 10.1% will be allocated to fund pipeline assets in preclinical stage; approximately 8.9% will be used to advance preclinical assets not yet in the preclinical application stage and strengthen our technology platform; approximately 8.1% will be used for working capital and other general corporate purposes.